C

CG Oncology Inc
NASDAQ:CGON

Watchlist Manager
CG Oncology Inc
NASDAQ:CGON
Watchlist
Price: 53.81 USD -3.65% Market Closed
Market Cap: $4.3B

Operating Margin

-8 285.3%
Current
Improving
by 8 124.2%
vs 3-y average of -16 409.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-8 285.3%
=
Operating Income
$-180.1m
/
Revenue
$2.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-8 285.3%
=
Operating Income
$-180.1m
/
Revenue
$2.2m

Peer Comparison

Country Company Market Cap Operating
Margin
US
CG Oncology Inc
NASDAQ:CGON
4.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 14 112 companies
4th percentile
-8 285.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

CG Oncology Inc
Glance View

Market Cap
4.3B USD
Industry
Biotechnology

CG Oncology Inc. is navigating the turbulent waters of biotechnology with a laser focus on the treatment of bladder cancer. Rooted deeply in the realm of oncolytic immunotherapy, the company harnesses the power of genetically modified viruses to selectively infect and destroy cancer cells. Their flagship product, CG0070, is at the heart of this endeavor, utilizing a modified adenovirus that targets tumors after traditional treatments have failed or when they present a significant clinical challenge. This targeted approach not only aims to disrupt tumor growth directly but also to stimulate a broader immune response, turning the patient's own defenses against the malignant invaders. Commercial success in this niche is predicated on the ability to navigate a highly regulated space with lengthy clinical trials and significant investment in research and development. CG Oncology makes money by progressing its therapies through these clinical development stages, eventually securing regulatory approvals. The ultimate goal is to partner with larger pharmaceutical companies or independently bring their treatments to market, capitalizing on licensing agreements, sales, and milestone payments. This reflects a strategy commonly seen in the biotech sector, where innovation and partnerships drive revenue, turning cutting-edge science into viable, life-extending products for patients and profitable ventures for investors.

CGON Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-8 285.3%
=
Operating Income
$-180.1m
/
Revenue
$2.2m
What is CG Oncology Inc's current Operating Margin?

The current Operating Margin for CG Oncology Inc is -8 285.3%, which is above its 3-year median of -16 409.5%.

How has Operating Margin changed over time?

Over the last 2 years, CG Oncology Inc’s Operating Margin has increased from -27 180.9% to -8 285.3%. During this period, it reached a low of -28 546.1% on Jun 30, 2025 and a high of -8 285.3% on Oct 30, 2025.

Back to Top